Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Finnish biopharmaceutical firm Faron, China Medical Systems (CMS) and A&B have entered into a strategic agreement to develop and commercialize traumakine to treat moderate to severe acute respiratory distress syndrome (ARDS).
Subscribe to our email newsletter
Under the deal, CMS has secured exclusive assets and rights for the development and commercialisation of Faron’s lead drug candidate traumakine in China, Hong Kong, Macao and Taiwan (the Territory).
This year, traumakine is entering a pan-European Phase III trial and has the potential to be the first pharmaceutical treatment of moderate to severe acute respiratory distress syndrome, a condition that kills 35-45% of ICU patients despite ventilation assisted supportive therapies.
Positive results from the Phase II trial conducted in the UK showed more than 80% reduction in mortality in the Traumakine treatment group.
The company said that after successful pan-European Phase III trial of traumakine in Europe, market authorization and licenses will be given for the development and commercialization of the product in the Territory.
Hong Kong-based investment and development company A&B, which has made an equity investment of €5m in Faron, will be responsible for all further development costs of the product in the Territory.
Earlier in 2011, Faron agreed with Japanese pharmaceutical firm Maruishi to develop and commercialise traumakine in Japan.